Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
NASHVILLE, Tenn., April 02, 2024 BUSINESS WIRE )--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre-money valuation that increased nearly 150% from the pre-money valuation for Melt's Series A Preferred Stock financing in 2019. The capital raised will primarily support the further development of MELT-300, including the MELT-300 Phase 3 program. MELT-300, a non-IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg), is administered sublingually using Catalent Inc.'s proprietary fast-dissolving Zydis® delivery technology to rapidly dissolve the tablet for absorption across the very thin sublingual mucosa. The MELT-300 Phase 3 program commenced in the first quarter of 2024, with first patient dosing expected in the second quarter of 2024
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) InvestigationAccesswire
- Catalent, Novo Nordisk receive FTC request for more information [Seeking Alpha]Seeking Alpha
- US FTC seeks more information on Novo Nordisk parent-Catalent deal [Reuters]Reuters
- FTC seeks more information on Novo Holdings-Catalent deal [Yahoo! Finance]Yahoo! Finance
- Here's How Novo Holdings' Catalent (CTLT) Acquisition Affects Laughing Water Capital [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 5/3/24 - Form DEFA14A
- 5/3/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- CTLT's page on the SEC website